logo
logo

D3 Bio Launches with US$200 Million Investment to Develop Precision Medicines Addressing Unmet Patient Needs in Oncology & Immunology

Nov 17, 2020•almost 5 years ago

Amount Raised

$200 Million

Shanghai

Description

D3 Bio, a global biotechnology company focused on developing and commercializing precision medicines to improve or replace existing standard-of-care treatments that do not fully meet patient needs, launched today with US$200 million Series A financing by Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec’s Corporate Venture Fund, among others. The funding will support the development of D3 Bio’s portfolio in oncology and immunology.

Company Information

Company

D3 Bio

Location

Shanghai, Shanghai, China

About

D3 Bio is a China-based, globally-focused biotechnology company developing and commercializing paradigm-shifting precision medicines to improve or replace existing oncology and immunology standard-of-care treatments that fail to or don’t fully meet significant patient needs. D3 Bio collaborates with world-class partners across many geographic areas, integrating deep clinical and market insights about the healthcare treatment landscape with disruptive science and technological development through a progressive, iterative cycle of Development to Discovery and back to Development. For more information, please visit http://www.d3bio.com

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech